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Abstract
Introduction: The adult mammalian brain retains niches for neural stem cells (NSCs), which can generate glial and
neuronal components of the brain tissue. However, it is barely established how chronic neuroinflammation, as it
occurs in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease, affects adult neurogenesis and,
therefore, modulates the brain’s potential for self-regeneration.
Methods: Neural stem cell culture techniques, intraventricular tumor necrosis factor (TNF)-a infusion and the
6-hydroxydopamine mouse model were used to investigate the influence of neuroinflammation on adult
neurogenesis in the Parkinson’s disease background. Microscopic methods and behavioral tests were used to
analyze samples.
Results: Here, we demonstrate that differences in the chronicity of TNF-a application to cultured NSCs result in
opposed effects on their proliferation. However, chronic TNF-a treatment, mimicking Parkinson’s disease associated
neuroinflammation, shows detrimental effects on neural progenitor cell activity. Inversely, pharmacological
inhibition of neuroinflammation in a 6-hydroxydopamine mouse model led to increased neural progenitor cell
proliferation in the subventricular zone and neuroblast migration into the lesioned striatum. Four months after
surgery, we measured improved Parkinson’s disease-associated behavior, which was correlated with long-term anti-
inflammatory treatment. But surprisingly, instead of newly generated striatal neurons, oligodendrogenesis in the
striatum of treated mice was enhanced.
Conclusions: We conclude that anti-inflammatory treatment, in a 6-hydroxydopamine mouse model for
Parkinson’s disease, leads to activation of adult neural stem cells. These adult neural stem cells generate striatal
oligodendrocytes. The higher numbers of newborn oligodendrocytes possibly contribute to axonal stability and
function in this mouse model of Parkinson’s disease and thereby attenuate dysfunctions of basalganglian motor-
control.
Introduction
Parkinson’s disease (PD) is the second most prevalent neu-
rodegenerative disorder with a prevalence of over 1% after
the age of 65 years [1]. The pathology of PD is character-
ized by a selective loss of dopaminergic neurons (DA) in
the substantia nigra (SN), causing motor dysfunction. As a
driving force for PD progression uncontrolled, chronic
neuroinflammation has been described [2]. However, it is
not before 50 to 60% of DA neurons and 70 to 80% striatal
DA nerve terminals are lost that those dysfunctions, lead-
ing to diagnosis of PD, become apparent [3]. Therefore,
neuro-regenerative approaches aiming for the replacement
of lost cells or the functional improvement of the still
available axonal projections are needed. Ideally, such
approaches make use of the intrinsic regenerative capacity
of the adult brain that is hidden in its largest neural stem
cell niche, the subventricular zone (SVZ) [4,5]. Under phy-
siological conditions GFAP+ neural stem cells from the
adult SVZ continuously generate fate committed neuro-
blasts that can migrate into the olfactory bulbs to differ-
entiate into interneurons [4,6,7].
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However, under acute pathological situations, for
example, after ischemic stroke, it has been shown that a
fraction of these neuroblasts have the potential to
migrate to the site of the lesion, where they differentiate
into mature neurons [5,8]. Unfortunately, due to low sur-
vival rates and other detrimental effects, no significant
regeneration has been shown so far [8-10]. Nevertheless,
it is conceivable that such a pro-regenerative migration
could also occur in PD, either into the striatum, where
DA axons are degenerated, or directly to the SN. Inter-
estingly, as a reaction to striatal TGF-a infusion, such a
precursor cell migration in PD rat brains has been
described before [11]. Still, in contrast to the acute
pathogenesis of ischemic stroke, the PD associated neu-
roinflammation is chronic [2,12,13]. But how this chronic
neuroinflammation affects the regenerative capacity of
the adult mammalian brain remains very unclear. There-
fore, in this study we analyzed the effects of PD asso-
ciated chronic neuroinflammation on the activity of adult
neural stem cells in the SVZ.
Materials and methods
Antibodies
The following antibodies were used: anti-Nestin (BD
Bioscience, Franklin Lakes, NJ, USA), anti-Ki67 (Vector
Labs, Burlingame, CA, USA), anti-Ki67 (BD Bioscience),
mouse-anti-Tuj1 (Covance, Princeton, NJ, USA), rabbit-
anti-Tuj1 (Covance), anti-Dcx (Millipore, Billerica, MA,
USA), anti-Dcx (Abcam, Cambridge, UK {), anti-
TH (Abcam), anti-TH (Millipore), anti-GST-π (BD
Bioscience), anti-NeuN (Millipore), anti-P-H3 (New
England Biolabs, Ipswich, MA, USA), anti-P-H3 (Milli-
pore), mouse-anti-GFAP (Millipore), chicken-anti-GFAP
(Millipore) and anti-cleaved-caspase-3 (Cell Signaling
Technology, Danvers, MA, USA). Alexa-fluorophore
conjugated antibodies (Invitrogen, Carlsbad, CA, USA)
were used as secondary antibodies for immunofluores-
cence staining. DNA was stained with Hoechst 33342
(Invitrogen).
Mice
All animal experiments were performed on wildtype C57/
Bl6 inbred mice (approximately 20 g). Mice were kept
under standard conditions according to governmental
rules and regulations. All animal experiments were per-
formed according to governmental rules. In all experi-
ments, except those that focus on the influence of aging,
40- to 60-day-old animals were used. For the aging experi-
ments, 12- to 13-month-old mice were used.
Neural stem cell culture
Neural stem cells were cultured as previously described
[14,15]. Murine E12.5-E14.5 embryonic brain derived
neural stem cells (NSCs) were grown on poly-D-Lysine-
coated dishes in maintenance medium consisting of NS-A
medium (Euroclone, Milan, Italy) supplemented with b-
FGF2 (Peprotech, Rocky Hill, NJ, USA), EGF (Peprotech),
N2-Supplement (Invitrogen), Pen/Strep (Invitrogen)
and L-Glu (Invitrogen). For induction of neuronal differen-
tiation, the medium was changed to NS-A medium
(Euroclone, Milan, Italy) supplemented with b-FGF2
(Peprotech), N2-Supplement (Invitrogen), B27 Supplement
(Invitrogen), Pen/Strep (Invitrogen) and L-Glu (Invitrogen).
For immunofluorescence stainings, NSCs were seeded onto
coated glass coverslips in 24-well plates. TNF-a was diluted
to a final concentration of 10 ng/ml in either maintenance
or differentiation medium and applied to the cells by med-
ium exchange.
RNA isolation, cDNA production and PCR
NSCs were grown under maintenance conditions and
RNA was isolated using the RNeasy Mini Kit (Qiagen N.
V., Hilden, NRW, Germany) following the manufac-
turer’s instructions. Subsequently, cDNA was generated
with SuperScript II Reverse Transcriptase (Invitrogen)
and PCR was performed using the SYBR Green Jump-
Start Taq ReadyMix (Sigma-Aldrich, St. Louis, MO,
USA), both following manufacturer’s instructions.
The following primer were used: TNFRSF1a for
(TGCGTCCCTTGCAGCCACTG), TNFRSF1a rev (TCC
AGGCACCCAGCCAGGTT), TNFRSF1b for (TGAG
GCTGAGCAAGTGCGGC), TNFRSF1b rev (GGCA
CGGGCCTCCTGAAACC), RIPK1 for (GCCCAACCGC
GCTGAGTACA), RIPK1 rev (GCCAGCACCGCTCCAT-
GAGG), RelA for (GCAGTGCGCCTCTGCTTCCA),
RelA rev (CAGGGACTGGGGAGGACCCG), MADD for
(GGATGACGCCCGGCAGGATG), MADD rev (GGCCC
GTCACCTGCATTGCT), TANK for (ACGCGAGCAA-
CAGGAACAGC), TANK rev (CTCGGGGCCTCTGG
AGTGCT), GAPDH for (TTGGCCGTATTGGGCGC
CTG), GAPDH rev (TCTCCAGGCGGCACGTCAGA), g-
Actin for (CTGCGCTTCTTGCCGCTCCT), g-Actin rev
(CCCGTCGGGCAGCTCGTAAC).
Osmotic mini-pump implantation
Osmotic mini-pumps (Alzet Osmotic Pumps, Cupertino,
CA, USA, model 1002, 0.25 µl flow rate, brain infusion kit
3) for 14-day long TNF-a infusion were filled according to
the manufacturer’s protocol with either sterile saline (0.9%
NaCl w/v) or with saline + 10 ng/ml TNF-a (Peprotech)
under a sterile hood. Implantation was done using a
stereotactic frame (David Kopf Instruments, Tujunga, CA,
USA, model 940). Animals were anesthetized with 2.5%
Avertin at a dose of 20 ml/kg by intraperitoneal (i.p.) injec-
tions and fixed into the stereotactic frame. Osmotic
pumps were implanted subcutaneously on the back of the
animal and connected via a flexible tube to a 30-gauge
infusion cannula and inserted into the lateral ventricle
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(stereotaxic coordinates AP: 0 mm, ML: -0.84 mm (both
from bregma), DV: 2.5 mm from the skull).
6-OHDA Parkinson’s disease model
6-Hydroxy-dopamine (6-OHDA, Sigma-Aldrich, St.
Louis, MO, USA) was dissolved at 5 mg/ml in 0.02%
ascorbic acid/0.9% NaCl (w/v) [16]. For surgeries mice
were anesthetized with 2.5% Avertin and placed into a
stereotactic frame. Bregma and lambda were adjusted to
the same horizontal plane and their distance was mea-
sured. If this distance × was more or less than 3.8 ±
0.2 mm, a correction factor y was multiplied with all
stereotactic coordinates (y = x/3.8). Stereotactic coordi-
nates for the substantia nigra were obtained from Frank-
lin and Paxinos Mouse Brain Atlas (AP: -3 mm, ML:
-1.5 mm (both from bregma), DV: 4.4 mm below skull).
Injection was done using a Hamilton 7005KH 5 µl syr-
inge connected to Model 5000 Microinjection Unit with
Model 5000-G Course Adjustment Handle (both David
Kopf Instruments). The cannula was lowered slowly
within one minute to target coordinates and 2 µl of either
6-OHDA or control solution (ascorbic acid/NaCl) were
injected within about three minutes. Before the cannula
was ejected, it was left in place for two minutes.
Minocycline and NS-398 treatment
Minocycline hydrochloride (Sigma-Aldrich) dissolved in
saline was either administered once per day by intraperi-
toneal (i.p.) injections at 45 mg/kg [17] on days 15 to 24
post surgery (dps), followed by perfusion of the animal at
24 dps, or for long-term treatment via drinking water at
0.12 mg/ml, protected from light and exchanged every
second day for 15 weeks [18] until perfusion of the mice.
Here, normal drinking water was used as the control.
NS-398 (N-[2-(cyclohexyloxy)-4-nitrophenyl]-metha-
nesulfonamide, Cayman Chemical, Ann Arbor, MI,
USA) was administered at 10 mg/kg in DMSO/1 ×
phosphate-buffered saline (PBS) (1:3) by i.p. injections
[19] once per day on days 15 to 24 post surgery, fol-
lowed by perfusion of the animal at 24 dps.
EdU and BrdU administration
The uridine analogue EdU (5-ethynyl-2’-deoxyuridine,
Invitrogen) was administered by i.p. injections at 25 mg/kg
twice per day at 11 dps or at 21 dps (as indicated) in the
morning and evening.
In the Minocycline long-term experiment EdU was
injected i.p. at 25 mg/kg once per day at three consecu-
tive days (70 to 72 dps). Additionally, a second uridine
analogue, BrdU (5-bromo-2-deoxyuridine, Sigma-
Aldrich), was administered by drinking water (0.8 mg/
ml) in the drinking bottle together with Minocycline for
14 days (85 to 97 dps).
Immunocytochemistry
Cells were fixed with 4% PFA/1xPBS for 15 minutes at
RT, permeabilized with cold 0.05% Triton X-100/1 ×
PBS for 3 minutes on ice and blocked with 10% fetal
calf serum (FCS) in 1 × PBS for 1 h at RT on a shaker.
The cells were subsequently incubated with primary and
secondary antibodies in FCS solution and mounted in
AquaMount (Dako Denmark A/S, Glostrup, Denmark).
Immunohistochemistry
Animals were anesthetized followed by intracardial per-
fusion with 50 ml 1 × PBS and then with 50 ml 4% PFA/
1 × PBS solution. The brains were isolated and then
immersed in 4% PFA in a rolling 50 ml tube overnight at
4°C. Preparation of 40 µm sagittal brain sections was
done with a Vibratome (VT 1200 S, Leica Microsystems,
Wetzlar, HE, Germany) and the slices were permeabilized
afterwards for at least 1 h at 4°C in Tris-buffered saline
(TBS)+++ (TBS 0.1 M Tris, 150 mM NaCl, pH 7.4/0.5%
Triton-X 100/0.1% Na-Azide/0.1% Na-Citrate/5% normal
goat serum) floating in 24-well plates on a shaker. For
immunostaining, sections were incubated in 250 µl TBS+
++ containing primary antibodies for 2 days on a shaker
at 4°C, followed by 2 h incubation with secondary antibo-
dies and Hoechst 33342 in TBS+++ at RT. Finally,
sections were mounted in AquaMount (Dako).
EdU detection was performed according to the manu-
facturer’s protocol (Invitrogen).
Microscopy and cell counting
Microscopy and counting of cultured neural stem cells
was performed with a Zeiss Axiovert 40 microscope. Sagit-
tal brain sections were analyzed with a Zeiss LSM 710
confocal microscope. EdU+ and Dcx+ cells in the SVZ and
proximal rostral migratory stream (pRMS) were imaged
non-saturated (standardized by using the Range Indicator
option) as confocal Z-stack throughout the entire
z-dimension of the sections. Each optical section of these
Z-stacks was analyzed with the Cell Profiler cell image
analysis software (Broad Institute, Cambridge, MA, USA)
[20,21] in order to count EdU+ and Dcx+ cells. Therefore,
the program first set the fluorescence intensity of each
channel to the range of 0 to 1, with 0 being a defined cut-
off value and 1 being the highest measured value per
image. Subsequently, it identified the nuclei as primary
objects and then, in a radius of one (EdU) or five (Dcx)
pixels around the nuclei, it measured either the fluores-
cence of the EdU or Dcx channel as secondary objects. All
secondary objects with fluorescence intensity below a
given threshold were counted as negative, those above the
threshold as positive. For all images in an experiment the
same parameter settings (pipelines) were used in Cell Pro-
filer. As a control for the computer-based counting, we
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manually counted images of the TNF-a infusion and the
NS-398 experiments. Those quantifications led to essen-
tially the same results as the automated cell counting via
Cell Profiler (Broad Institute, Cambridge, MA, USA).
Migration of Dcx+ neuroblasts into striatum was ana-
lyzed by ImageJ software with LSM Reader plug-in
(National Institutes of Health (NIH), Bethesda, MD,
USA). Cartesian coordinates were assessed of the border
of the anterior wall of the lateral ventricle and of Dcx+
cells in the SVZ and the striatum on confocal TILE
scans and the length of the shortest vector between ven-
tricular wall and cell was calculated and counted.
Behavioral experiments
For the Rotameter test the animals were i.p. injected with
5 mg/kg amphetamine hydrochloride (Sigma-Aldrich)
and placed into a transparent cylindrical container (Rota-
meter, Harvard Apparatus, Holliston, MA, USA). After
10 minutes of habituation, animal behavior was recorded
with a high resolution webcam for 20 minutes. The
resulting movies were analyzed for the amount of rota-
tions per mouse. After the movies were taken, the mice
were fixed into an adjustable harness connected by a flex-
ible wire to a digital rotation sensor (LE 902/Sr, Harvard
Apparatus), which counted the rotation of the mice at
four points of a complete circle. After five minutes of
habituation, measurement was started. Video (data not
shown) and harness analysis showed the same tendencies
between control and Minocycline treated animals.
Statistical analysis
Statistical analysis was done using Microsoft Excel
(Microsoft, Redmond, WA, USA) and SigmaPlot (Systat
Software, Inc., San Jose, CA, USA). Statistical tests were
used as indicated in the figure legends. The number of
animals used in each experiment was as indicated in the
figure legends. All statistics from cell culture experi-
ments are based on 700 to 1,450 counted cells. For the
migration experiments, between 3,000 to 16,850 nuclei
were counted per treatment group. For the EdU and
Dcx quantifications in the pRMS and the SVZ between
14,400 to 41,600 nuclei were counted per treatment
group.
Ethical considerations
All animal experiments were conducted in accordance
with the German Federal law on the Care and Use of
laboratory animals. The corresponding licenses were
granted by the Landesamt fuer Natur, Umwelt und Ver-
braucherschutz Nordrhein-Westfalen (Germany).
Results
Among the factors characterizing neuroinflammation is
the pro-inflammatory cytokine TNF-a, which is released
by activated microglia cells [22]. In vitro neural stem
cells only express the TNF-a Receptor I (TNFRI), but
not the TNFRII (Additional file 1, Figure S1). Addition-
ally, components of the downstream nuclear factor
‘kappa-light-chain-enhancer’ of activated B-cells (NF-
B)- and mitogen-activated-protein-kinase (MAPK)-
pathways are expressed.
Because the chronicity of neuroinflammation in differ-
ent disease situations varies, we started to investigate the
differences in the NSCs’ reaction to acute and chronic
increases in TNF-a level. Therefore, we applied 10 ng/ml
TNF-a in vitro on NSCs either acutely (2 h prior to fixa-
tion) or chronically for eight days. Interestingly, acute
treatment significantly increased the mitotic index (phos-
pho-Histone H3 staining) (Additional file 1, Figure S2A,
B, D), while chronic treatment decreased NSC prolifera-
tion, as shown by reduced numbers of proliferating Ki67+
cells (Figure 1A, C). However, both treatments had no
effect on the NSCs’ ability to maintain expression n of
the neural stem cell marker Nestin, indicating that their
stemness was not affected (Figure 1A, C; Additional file
1, Figure S2B, C). Nevertheless, under cell culture condi-
tions that allow those NSCs to undergo neuronal differ-
entiation, chronic TNF-a treatment (eight days) led to
reduced neuronal differentiation (as shown by TuJ1
expression) (Figure 1B, D). Because TNF-a is known to
be able to induce Caspase dependent apoptosis [23], we
also investigated cleaved-caspase-3 appearance in chroni-
cally treated cultures. However, in those NSCs we never
detected a TNF-a mediated increase in apoptosis under
the applied experimental conditions (Additional file 1,
Figure S3). Together this suggests that in vitro TNF-a
can affect NSC proliferation and differentiation both posi-
tively and negatively, depending on the chronicity of
treatment.
In the next step, we specifically wanted to address the
impact of chronic neuroinflammation on adult neural
stem cells in vivo in the SVZ. To mimic an aspect of
chronic neuroinflammation we infused TNF-a continu-
ously for 14 days into the lateral ventricle of the mouse
brain (Figure 2A) [24]. At 11 days after the start of the
TNF-a infusion, the animals received an injection of the
uridine analogue EdU to label proliferating cells. Finally, at
14 days after the start of the infusion, the animals were
sacrificed and the brains were fixed and processed for
immunostainings. To analyze the activity of adult neural
stem cells, we assessed the number of newly generated
cells (EdU+) as well as the number of neuroblasts (Double-
cortin+, Dcx+), which were normalized with the number of
Hoechst+ nuclei (percentage of immunofluorescence stain-
ing positive cells of total cell number per animal: EdU-/
Dcx-index). Both factors were analyzed in the SVZ and
the proximal/sprouting rostral migratory stream (pRMS).
For both, SVZ and pRMS, we observed a significant
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reduction in the number of EdU+ and Dcx+ cells (Figure
2B-D; Additional file 1, Figure S4 and Tables S1 and S2).
The reduction in the number of EdU+/Dcx+ double-
positive cells was comparable to the reduction in the
EdU-index, suggesting that the loss of proliferation
depends strongest on decreased generation or proliferation
of Dcx+ neuroblasts. It is conceivable that Dcx+ neuro-
blasts are directly regulated by TNF-a. This is in agree-
ment with our observation, that Dcx+ cells are highly
labeled, when stained with an anti-TNF-a antibody (data
not shown). From this set of experiments, we conclude
that chronic exposure to TNF-a (as a model of chronic
neuroinflammation) reduces the amount of adult
SVZ neurogenesis, by decreased generation of Dcx+
neuroblasts.
Next, we established an in vivo PD mouse model [16],
induced by unilateral stereotactic injection of 6-Hydro-
xydopamine (6-OHDA) directly into the SN [25].
Following the injection of 6-OHDA, nigral DA neurons
degenerated almost completely (>90%), as seen by loss
of neuronal cell bodies positive for the DA neuron mar-
ker Tyrosine Hydroxylase (TH) (Figure 3A; Additional
file 1, Figure S5B). Additionally, a reduced innervation
of the ipsilateral striatum (close to the NSC containing
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SVZ) by DA neurons became visible (Figure 3A). The
animals were either sham operated or injected with 6-
OHDA (Additional file 1, Figure S5A). To investigate
the effect of anti-inflammatory treatment on NSCs fol-
lowing the injection of 6-OHDA, the animals received
10 daily injections either of the semi-synthetic tetracy-
cline derivative Minocycline, which was previously
shown to attenuate microglia activation [26], or the
vehicle as control. To ensure that acute post-surgery
side-effects would not interfere with the experiment, the
Minocycline treatment was not started until 14 days
post-surgery (dps). Furthermore, this time span ensured
complete DA neuron degeneration within the SN prior
to the start of Minocycline treatment. Thus, it could be
ruled out that the potential effects of Minocycline were
due to neuronal protection of dopaminergic neurons in
the SN, but rather due to changes in the NSC activity
following inhibition of neuroinflammation. At 21 dps
the animals received two injections of EdU to label pro-
liferating cells. Finally, at 25 dps, the animals were sacri-
ficed and the brains were processed for immunostaining.
We first analyzed the EdU index in the pRMS.
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Interestingly, we found no significant differences in the
number of newborn EdU+ cells in the sham groups (+/-
Minocycline) and the 6-OHDA group without Minocy-
cline (Figure 3B, C; Additional file 1, Table S3). How-
ever, within the 6-OHDA group that received
Minocycline, the percentage of newborn EdU+ cells was
increased by 1.6- to 1.7-fold compared to all other treat-
ment groups.
In all treatment groups we found Dcx+ neuroblasts
located in the striatum, which in the 6-OHDA groups
showed degeneration of DA projections. Subsequently,
we were interested, whether the Minocycline-induced
increase in NSC activity would also lead to increased
production of neuroblasts that migrate into the lesioned
striatum, where they potentially could have regenerative
effects. Therefore, we analyzed the position of Dcx+
neuroblasts relative to the anterior wall of the lateral
ventricle. And indeed, in the 6-OHDA group, which
additionally received Minocycline injections, the propor-
tion of neuroblasts that had migrated deeply (50 µm
and more) into the lesioned striatum was increased 2-
to 3.9-fold compared to all other groups. (Figure 3D, E;
Additional file 1, Figure S6 and Table S4).
To ensure that the observed effects are indeed due to
the inhibition of neuroinflammation, and not to an
unspecific side effect of Minocycline treatment, we
repeated the experiment, using the selective Cox-2 inhi-
bitor NS-398 [19]. In support of the before described
results, treatment with NS-398 essentially recapitulated
the findings achieved with Minocycline (Additional file 1,
Figures S7 and S8, and Tables S5 and S6). One of the
major risk factors for Parkinson’s disease is increasing
age. Also, it is assumed that the overall level of neuroin-
flammation increases with aging [27]. So, we repeated the
Minocycline treatment using aged (12- to 13-month-old)
6-OHDA-lesioned and sham mice. Also here, we found
an increase in the number of EdU+ cells in the pRMS
(Additional file 1, Figure S9 and Table S7). Taken
together, anti-inflammatory treatment after degeneration
of DA neurons in the SN increased the activity of adult
SVZ NSCs and led to the generation of neuroblasts that
migrate deeply into the lesioned striatum.
Finally, we were interested in addressing which fate
those migrating neuroblasts might acquire within the
lesioned striatum after longer time periods. To analyze
this, we again stereotactically injected 6-OHDA unilater-
ally into the SN of mice. Three weeks post-surgery one
group of mice received Minocycline with their drinking
water over a period of 14 weeks while the other group of
mice received normal drinking water (Figure 4A). The
addition of Minocycline to the drinking water had no
effect on the drinking behavior of those mice. To be able
to assess the numbers and celltypes of surviving newly
generated cells in the ipsilateral striatum, all mice
received daily injections of EdU at 70 to 72 dps. Addi-
tionally, between 85 dps and 97 dps the mice received
BrdU via their drinking water to assess the numbers and
cell types of newly generated cells in a second, broader
time window. For this utilized model of PD (unilateral
6-OHDA injection) a rotation phenotype after injection
of amphetamine has been described [28]. Therefore, we
analyzed the rotational behavior after injection of amphe-
tamine in the two treatment groups (with and without
Minocycline treatment) at 115 to 119 dps via a Rota-
meter. Strikingly, in the group of mice that received
Minocycline, the number of turns was indeed reduced
significantly (Figure 4B; Additional file 1, Table S8). This
indicates that Minocycline treatment induced a func-
tional regeneration that depends on DA neuron activity
in those mice.
Based on the above described encouraging results from
behavioral experiments, we were interested in the cellular
effects that underlie this regenerative phenotype. Thus,
the brains of those mice were fixed and processed for
immunostaining at 123 dps. Fixation at this time-point
provided enough time for the potential differentiation of
EdU+ or BrdU+ SVZ derived Dcx+ neuroblasts (51 to 53
days for EdU labeling; 26 to 38 days for BrdU labeling).
Although we found a large amount of EdU+ and BrdU+
cells within the striatum and the SN, to our surprise
none of these cells were positive for the DA neuron mar-
ker TH or the mature neuronal marker NeuN (data not
shown). Nevertheless, the total amount of newly gener-
ated EdU+ cells that had migrated into the dorsal stria-
tum (Figure 4C) was also increased upon treatment with
Minocycline in this long-term experiment (Figure 4D;
Additional file 1, Table S9). This parallels our findings
about the striatal immigration of Dcx+ cells from the
shorter anti-inflammatory treatments (Figure 3; Addi-
tional file 1, Figure S7). Interestingly, many of these EdU+
nuclei were in close proximity to NeuN+ neurons.
Furthermore, these cells were often localized in or adja-
cent to the white matter of the striatum. Therefore, we
reasoned that a large fraction of the newly generated cells
could have differentiated into oligodendrocytes. To verify
if this was indeed the case, we performed co-stainings of
EdU with the mature oligodendrocyte marker GST-π.
In the dorsal striatum we indeed detected an increase in
the fraction of EdU+/GST-π+ among EdU+ cells in the 6-
OHDA/Minocycline group (29% (EdU+/GST-π+)/EdU+)
compared to the 6-OHDA group (15% (EdU+/GST-π+)/
EdU+) (Figure 4E, F; Additional file 1, Table S9). Hence,
after treatment with Minocycline, there were not only
more newly generated cells (EdU+) in the lesioned stria-
tum, but also the amount of these newly generated
cells that differentiated into mature oligodendrocytes
(EdU+/GST-π+)/EdU+) was significantly increased. As an
internal control, we investigated oligodendrogenesis in
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the corpus callosum (Additional file 1, Table S9). There,
we did not detect any differences between the Minocy-
cline group (77% GST-π+/EdU+) and the control group
(82% GST-π+/EdU+), indicating that the effect observed
in the lesioned striatum was indeed associated with the
6-OHDA induced degeneration of DA neurons in the
SN. In summary, our findings demonstrate that anti-
inflammatory treatment, in a 6-hydroxydopamine mouse
model for Parkinson’s disease, leads to activation of adult
neural stem cells. These adult neural stem cells generate
striatal oligodendrocytes.
Discussion
Interestingly, in our PD model the capacity of SVZ NSCs
to proliferate and to generate neuroblasts seems to be
maintained after degeneration of DA neurons in the SN
and of their projections in the striatum (Figure 3). This is
in line with most recent findings that show maintained
levels of NSC proliferation in the SVZ of PD patients
[29], but in contrast to previous publications, which show
a dependency of neural progenitor cell turn-over on
dopaminergic innervations [30,31]. However, when this
degeneration was followed by an anti-inflammatory
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treatment, the activity of NSCs increased significantly
above the control level. Taking into account, that chronic
treatment with the pro-inflammatory cytokine TNF-a
inhibited the activity of adult neural stem cells in vitro
and in vivo, we come to the following conclusions:
DA neuron degeneration in the SN (and thereby also in
the targeted striatum) modulates the activity of adult
NSCs. On the one hand, several publications [8,9,32]
describe a stimulating effect of acute degenerative patholo-
gical situations like stroke on the activity of adult NSCs,
which eventually leads to increased generation of neuro-
blasts and their migration to the site of lesion. This migra-
tion probably is driven by soluble factors released from
microglia cells [32]. On the other hand, chronic neuroin-
flammation, as seen in neurodegenerative diseases like PD
[2], slows down the generation of neuroblasts, which is, at
least in part, due to chronically increased TNF-a levels
(Figures 1 and 2). Thus, in PD pathology, two counteract-
ing processes, the activation of the regenerative potential
in the SVZ, elicited by neuronal degeneration, and the
slowing down of NSC proliferation by chronic inflamma-
tion, cause a balance in neurogenesis. In our experiments
we pharmacologically inhibited the activation of microglia
cells after inducing degeneration of DA neurons. Thereby,
the negative neuroinflammation-associated effect was
abrogated, thus shifting the balance to a pro-regenerative
increase in SVZ neurogenesis (Figure 3; Additional file 1,
Figures S7 and S9). Here, similar to previous studies [33],
we did not detect any changes in the levels of neurogenesis
after Minocycline injection in sham animals. This indicates
that Minocycline does not directly affect the NSCs, but
that secondary effects, especially the inhibition of neuroin-
flammation, are causative for the enhanced progenitor cell
proliferation in 6-OHDA/Minocycline mice. As a result, a
net increase in neuroblast generation and intra-striatal
migration could be observed after anti-inflammatory treat-
ment in the 6-OHDA pre-treated group. Interestingly,
others found similar neuroblast migrations, after infusion
of growth factors, known to enhance neurogenesis, into
the Parkinsonian brain [11,34], which is in support of our
findings. Similarly supporting our conclusions are recent
findings of Ng et al. in a model of focal traumatic brain
injury, in which early stages of neurogenesis were stimu-
lated in the hippocampus and the SVZ after Minocycline
mediated attenuation of neuroinflammation [35].
Finally, when we prolonged the anti-inflammatory
treatment, we observed increased oligodendrogenesis in
the lesioned striatum, which might directly result from
enhanced progenitor cell proliferation in the SVZ by dif-
ferentiation of immigrated neuroblasts. These higher
numbers of newly generated oligodendrocytes were cor-
related with behavioral improvement of PD symptoms in
the Minocycline group of mice. Taking into account that
we did not find any newly generated striatal neurons,
which could have improved the basalganglion circuits,
oligodendrogenesis might be causative, at least in part,
for behavioral improvement of PD symptoms by increas-
ing the stability and efficiency of axonal function
of remaining ipsilateral or crossing contralateral DA
neurons.
In support of our conclusions of SVZ-derived
increased oligodendrogenesis, it has been reported that
during multiple sclerosis PSA-NCAM+/Sox10+/Olig2+
triple-positive cells are detectable in the white matter of
periventricular lesions in post-mortem human brain tis-
sue [36]. Similar observations have been made in mouse
models for multiple sclerosis [37]. So far, little is known
about the role of oligodendrocytes in PD. Nevertheless,
during synucleinopathies it has been shown that poorly
myelinated axons are more vulnerable than strongly
myelinated neurons [38]. Other studies have shown that
oligodendrocytes are vulnerable to oxidative stress [39]
and to pro-inflammatory cytokines [40,41], which both
occur in PD. Also, the leucine-rich repeat kinase 2 gene
(LRRK2), which in mutated forms contributes to familial
cases of PD, is expressed in oligodendrocyte cell lines
[42]. Importantly, a-synuclein inclusions have been
reported in oligodendrocytes in post-mortem PD tissue,
but not in control tissue [43,44]. Wakabayashi et al. also
found that these glial a-synuclein inclusions correlate
with the severity of PD symptoms. Furthermore, also in
the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridin (MPTP)
model of PD a degeneration of striatal oligodendrocytes
has been reported [45]. All these observations argue for
an important function of oligodendrocytes during the
PD pathology and support our conclusion that oligoden-
drocyte regeneration could be highly beneficial for PD
therapy.
Additionally, our study provides further evidence for
conclusions from previous studies, showing that effects
of neuroinflammation on adult neurogenesis are context
dependent and can be both stimulating and detrimental
[32,46]. Interestingly, our experiments show that not
only the elsewhere described differences in the time
course of (LPS dependent) microglia-activation have
diverse effects on neurogenesis [46], but even the differ-
ences in the chronicity of level-changes of a single cyto-
kine, TNF-a, can regulate NSC proliferation positively
and negatively (Figure 1; Additional file 1, Figure S2).
This conclusion might help to solve the controversies,
which still exist between studies that describe only nega-
tive or positive effects of single pro- or anti-inflamma-
tory mediators or even more complex inflammatory
responses from activated microglia or their conditioned
media [47-51].
Taken together, our results demonstrate a regenerative
effect of anti-inflammatory treatments that could be the
basis for therapeutic approaches aiming on endogenous
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adult neural stem cell-based cell replacement therapies
to treat neurodegenerative diseases.
Conclusions
Our results underline the importance of controlling
neuroinflammation in potential clinical approaches to
Parkinson’s disease that are based on endogenous neural
stem cells and their regenerative capacity. Further, our
findings also indicate that oligodendrocytes and oligo-
dendrogenesis are important players in the pathology of
Parkinson’s disease. Potentially, adult neural stem cell
based oligodendrogenesis represent a novel therapeutic
target in Parkinson’s disease treatment.
Additional material
Additional File 1: Figure S1. TNFRSF1a and downstream components of
MAPK- and NF-B pathway, but not TNFRSF1b, are expressed in cultured
murine NSCs. Agarose gel pictures after RT-PCR analysis are shown. On
the left: gene names; NSC: murine neural stem cells; N2d: NSCs two days
after induction of neuronal differentiation; N5d: NSCs five days after
induction of neuronal differentiation. Figure S2. Acute TNF-a treatment
of murine NSC culture increases mitotic index. (A) Experimental timeline.
(B) Representative immunofluorescence images showing NSC cultures
with and without TNF-a treatment, immunostained for Nestin, P-H3 and
Hoechst (DNA). (C) Quantification of Nestin staining in NSC cultures. (D)
Quantification of P-H3 staining in NSC cultures; *P ≤0.05 Student’s t-test,
error bars s.e.m. Figure S3. Chronic TNF-a treatment does not induce
apoptosis in NSC cultures. Co-immunostainings of cleaved-caspase-3 with
Nestin, Tuj1 or GFAP showed no difference in the number of apoptotic
cells in the three different cell types independently of the presence or
absence of TNF-a. Error bars s.e.m. Figure S4. Algorithm-based counting
of high numbers of optical sections per animal (up to 121 optical
sections per animal) was used for unbiased evaluation of EdU+- and Dcx
+- cell numbers in SVZ and pRMS. Upper panel: Confocal images
showing SVZ example of the three channels used as input for
automated cell counting with the Cell Profiler program. Lower panel:
detection of cells based on primary object detection of nuclei and
subsequent detection of secondary objects (EdU or Dcx
immunostaining). Figure S5. Injection of 6-OHDA efficiently induces
degeneration of dopaminergic neurons in the substantia nigra. (A)
Timeline and schematic overview of experimental setup for 6-OHDA/
Minocycline experiment. (B) Representative confocal TILE scans from the
substantia nigra of contra-lateral (non-injected) hemisphere and ipsilateral
(6-OHDA injected) hemisphere. Tyrosine Hydroxylase (TH)
immunostaining shows dopaminergic neurons. Nuclei-counterstaining
with Hoechst; dotted line indicates the interpeduncular fossa (IF). Figure
S6. Length of vectors of positions of Dcx+ cells in striatum relative to
ventricle lining in animals from Figure 3 (6-OHDA + Minocycline
experiment). Each diagram shows all distances from one particular
animal. Figure S7. Systemic administration of the selective Cox2-Inhibitor
NS-398 increases NSC proliferation in the pRMS in the 6-OHDA PD
mouse model. (A) Timeline showing experimental setup. (B) Confocal
images of the proximal RMS showing EdU stainings from 6-OHDA
lesioned animals with and without NS-398 treatment; dotted line
outlines the ventricle surface; quantified in (C), * P ≤0.1 Student’s t-test,
error bars s.e.m; number of animals: both groups n = 11. (D) Maximum
intensity projection of confocal TILE scans showing SVZ (top), RMS (right)
and striatum (center) with Dcx immunostainings and Dcx+ cells distant
from the SVZ in the striatum. Positions of Dcx+ neuroblasts and the
lining of the anterior ventricular wall were determined in Cartesian
coordinates and categorized according to the shortest vector length;
quantified in (E): differences in the fraction of Dcx+ cells per distance
category among total number of Dcx+ cells, * P ≤0.05 Mann-Whitney-U-
Test, error bars s.e.m., number of animals: 6-OHDA n = 10; 6-OHDA +
Minocycline n = 11. Figure S8. Length of vectors for positions of Dcx+
cells in striatum relative to ventricle lining in animals from Additional file
1, Figure S7 (6-OHDA + NS-398 experiment). Each diagram shows all
distances from one particular animal. Figure S9. Neuroinflammatory
effects on neurogenesis in aged 6-OHDA lesioned mice with minocycline
treatment shows a mild increase compared to aged sham mice without
minocycline treatment. (A) Timeline showing experimental setup. (B)
Confocal images of the proximal RMS showing EdU stainings from sham
animals without Minocycline treatment and 6-OHDA lesioned animals
with Minocycline treatment; dotted line outlines the ventricle surface;
quantified in (C), * P ≤0.1 Student’s t-test, error bars s.e.m.
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